<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The effects of medications on sleep quality and sleep architecture
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The effects of medications on sleep quality and sleep architecture
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The effects of medications on sleep quality and sleep architecture
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy Roehrs, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas Roth, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ruth Benca, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any medication that passes through the blood-brain barrier has the potential to alter the quality and/or architecture of sleep:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality is the degree to which restful sleep is maintained during the night and the individual feels refreshed on waking and throughout the day. Traditional measures of sleep quality include latency until sleep onset, wakefulness after sleep onset, and/or the duration of sleep.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture is the structure of sleep. It is cyclical, composed of rapid eye movement (REM) and several non-REM sleep stages, and assessed primarily by electroencephalography (EEG) during polysomnography.
        </p>
        <p>
        </p>
        <p>
         Medication-induced changes in sleep quality and/or architecture are not synonymous with a sleep disturbance; in some cases the changes may be therapeutic, while in others they may be benign or not well understood. The effects of medications that target the central nervous system, cardiovascular system, or respiratory system on sleep quality and sleep architecture are reviewed here. The stages and architecture of normal sleep are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7710.html" rel="external">
          "Stages and architecture of normal sleep"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CENTRAL NERVOUS SYSTEM MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Commonly prescribed medications that act on the central nervous system (CNS) and can affect sleep include benzodiazepines, nonbenzodiazepine receptor agonists, orexin antagonists, antiseizure drugs, antidepressants, analgesics, and CNS stimulants.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Benzodiazepines and nonbenzodiazepine receptor agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ) and nonbenzodiazepine receptor agonists (eg,
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         ,
         <a class="drug drug_general" data-topicid="10334" href="/z/d/drug information/10334.html" rel="external">
          zaleplon
         </a>
         ,
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         ) are commonly prescribed sedative-hypnotic medications used to treat insomnia or anxiety. Both types of agents facilitate gamma-aminobutyric acid (GABA)-mediated inhibition of cell firing by binding to a subunit of the GABA receptor complex called the benzodiazepine receptor. The GABA receptor complex is present throughout the brain, including the ventral lateral preoptic area that controls sleep.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – All benzodiazepines and nonbenzodiazepine receptor agonists improve sleep quality by reducing the time to sleep onset. The longer-acting agents also improve sleep quality by reducing wakefulness after sleep onset and increasing the total sleep time [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – Benzodiazepines and nonbenzodiazepine receptor agonists reduce the amount of stage N1 sleep (ie, light sleep), which is considered a therapeutic effect. They may also increase spindle activity during stage N2 sleep (and increase N2 percent). Benzodiazepines and the nonbenzodiazepine receptor agonists have differing effects on stage N3 sleep, which are of uncertain clinical significance. Finally, benzodiazepines and nonbenzodiazepine receptor agonists may modestly reduce rapid eye movement (REM) sleep when used at higher than indicated doses [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Patients report that their ease of falling asleep is improved, awakenings are reduced, and sleep time is increased. During the day they experience less sleepiness, greater ability to concentrate, and better daytime performance. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Benzodiazepine receptor agonists'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Discontinuation may be associated with rebound insomnia (ie, difficulty initiating or maintaining sleep that is worse than that experienced prior to the use of the medication), particularly if high doses are used [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4003072060">
         <span class="h2">
          Orexin receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         The neuropeptides orexin A and orexin B (also referred to as hypocretin1 and hypocretin 2) are thought to have a key role in the regulation of sleep and wake states. Orexin cells located in the hypothalamus activate monoaminergic and cholinergic neurons to produce long consolidated periods of wakefulness. In narcolepsy type 1, there is an absence of orexin in the cerebrospinal fluid (CSF). Three dual orexin receptor antagonists,
         <a class="drug drug_general" data-topicid="126415" href="/z/d/drug information/126415.html" rel="external">
          lemborexant
         </a>
         ,
         <a class="drug drug_general" data-topicid="96688" href="/z/d/drug information/96688.html" rel="external">
          suvorexant
         </a>
         , and
         <a class="drug drug_general" data-topicid="134764" href="/z/d/drug information/134764.html" rel="external">
          daridorexant
         </a>
         , are approved for the treatment of insomnia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – Orexin antagonists improve sleep onset and maintenance of sleep through all eight hours of the night. In patient-report outcomes, sleep quality is improved and insomnia scale scores are improved [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep stages – Orexin antagonists increase REM pressure, as evident by reduced REM latency [
         <a href="#rid6">
          6
         </a>
         ]. Other sleep stages are unaffected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rebound withdrawal – After one year of nightly use of
         <a class="drug drug_general" data-topicid="96688" href="/z/d/drug information/96688.html" rel="external">
          suvorexant
         </a>
         at doses up to 40 mg, there was no evidence of rebound or withdrawal effects [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Patients report more robust effects on sleep maintenance than on sleep initiation. Depending on dose and half-life, impaired next-morning driving performance has been reported. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Dual orexin receptor antagonists'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Melatonin and melatonin receptor agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9475" href="/z/d/drug information/9475.html" rel="external">
          Ramelteon
         </a>
         is a melatonin receptor agonist that binds to the melatonin 1 and 2 receptors (MT1, MT2), inhibiting the wakefulness-promoting activity of the suprachiasmatic nucleus [
         <a href="#rid8">
          8
         </a>
         ]. It is generally prescribed for the treatment of sleep onset insomnia (ie, difficulty falling asleep).
         <a class="drug drug_general" data-topicid="93720" href="/z/d/drug information/93720.html" rel="external">
          Tasimelteon
         </a>
         , also an MT1 and MT2 agonist, has been approved as a chronobiotic for the treatment of circadian rhythm sleep disorder and non-24-hour sleep-wake disorder [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Exogenous melatonin binds to all three melatonin receptors and is less potent than
         <a class="drug drug_general" data-topicid="9475" href="/z/d/drug information/9475.html" rel="external">
          ramelteon
         </a>
         . It is also considered a better chronobiotic agent than ramelteon, meaning that it is better at phase shifting circadian rhythms, although there are no direct comparisons [
         <a href="#rid8">
          8
         </a>
         ]. As a result, melatonin may be useful in circadian rhythm disorders, such as jet lag due to eastward travel and delayed sleep-wake phase syndrome. (See
         <a class="medical medical_review" href="/z/d/html/97845.html" rel="external">
          "Delayed sleep-wake phase disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7686.html" rel="external">
          "Jet lag"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Ramelteon'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality –
         <a class="drug drug_general" data-topicid="9475" href="/z/d/drug information/9475.html" rel="external">
          Ramelteon
         </a>
         and
         <a class="drug drug_general" data-topicid="93720" href="/z/d/drug information/93720.html" rel="external">
          tasimelteon
         </a>
         reduce the latency to sleep onset and increase sleep duration, although ramelteon's effects on sleep continuity are inconsistent. Melatonin also appears to reduce latency to sleep onset; however, its effects on sleep maintenance and duration are inconsistent [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture –
         <a class="drug drug_general" data-topicid="9475" href="/z/d/drug information/9475.html" rel="external">
          Ramelteon
         </a>
         reduces the amount of stage N1 sleep (ie, light sleep), which is considered a therapeutic effect, but it has no other effects on sleep architecture.
         <a class="drug drug_general" data-topicid="93720" href="/z/d/drug information/93720.html" rel="external">
          Tasimelteon
         </a>
         's sleep stage effects have not been reported. Melatonin's effects on sleep architecture are inconsistent [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Patients do not consistently experience increased sleep time or improved daytime function, but the ease of falling asleep improves.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Antiseizure drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Older antiseizure drugs (eg,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ) inhibit CNS activity, but the mechanisms of inhibition are poorly characterized. Other drugs (eg,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">
          tiagabine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) enhance GABA activity through various mechanisms.
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         , acts through a unique synaptic vesicle binding site. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – Antiseizure drugs such as
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         appear to decrease sleep latency and increase total sleep time [
         <a href="#rid12">
          12
         </a>
         ]. Phenobarbital may also decrease wakefulness after sleep onset. The effects of the newer agents on sleep quality are less certain due to a paucity of data. In separate studies,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         was associated with a trend toward fewer awakenings after sleep onset [
         <a href="#rid13">
          13
         </a>
         ],
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         was shown to reduce sleep latency and increase total sleep time [
         <a href="#rid11">
          11
         </a>
         ], and
         <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">
          tiagabine
         </a>
         had inconsistent effects on wakefulness after sleep onset and total sleep time [
         <a href="#rid14">
          14,15
         </a>
         ].
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         may improve sleep quality in healthy adults [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – The older antiseizure drugs have variable effects on sleep architecture.
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         appears to increase stage N3 sleep and reduce REM sleep.
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          Phenobarbital
         </a>
         decreases REM sleep, while
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         increases stage N1 sleep and decreases stage N3 sleep [
         <a href="#rid12">
          12
         </a>
         ]. The newer antiseizure drugs increase stage N3 sleep, while reducing REM sleep [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – The clinical significance of enhancement of stage N3 sleep is controversial. Whether patients experience improved sleep restoration or daytime function is yet to be determined.
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         may increase daytime sleepiness at high doses [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients tend to develop rapid tolerance (ie, within a week) to the sleep-related effects of the older antiseizure drugs, while tolerance to the newer agents is less evident [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antidepressant medications include the tricyclic agents (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin antagonist reuptake inhibitors (SARIs), and selective serotonin reuptake inhibitors (SSRIs). Most antidepressants affect both sleep quality and sleep architecture [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – Antidepressant agents have a variable effect on sleep quality, as some are sedating while others are stimulating. The tertiary TCAs (eg,
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , and
         <a class="drug drug_general" data-topicid="10025" href="/z/d/drug information/10025.html" rel="external">
          trimipramine
         </a>
         ) decrease the latency until sleep onset and wakefulness after sleep onset, whereas the secondary TCAs (eg,
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         and
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         ) have little or no effect on either measure [
         <a href="#rid10">
          10
         </a>
         ]. There is a paucity of data regarding the MAOIs (eg,
         <a class="drug drug_general" data-topicid="8991" href="/z/d/drug information/8991.html" rel="external">
          isocarboxazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">
          phenelzine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">
          tranylcypromine
         </a>
         ) but, generally speaking, they appear to increase wakefulness after sleep onset and decrease total sleep time [
         <a href="#rid12">
          12
         </a>
         ]. Studies of the effects of the SARIs (eg,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         and
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         ) on sleep quality are notable for their inconsistency, with about half of studies showing improvements in measures of sleep quality [
         <a href="#rid10">
          10
         </a>
         ]. Finally, the SSRIs (eg,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         ) appear to increase wakefulness after sleep onset and decrease the total sleep time [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – All antidepressant agents suppress REM sleep, except the SARIs [
         <a href="#rid10">
          10,12
         </a>
         ]. This is characterized by an increased latency to the onset of REM sleep and a reduction in the percentage of REM sleep. This is particularly profound with the MAOIs [
         <a href="#rid12">
          12
         </a>
         ]. Understanding the effects of antidepressant agents on the other sleep stages is complicated by inconsistent data. Many studies suggest that the tertiary TCAs have no effect on stage N3 sleep, although at least one study showed increased stage N3 sleep [
         <a href="#rid10">
          10
         </a>
         ]. Most studies have found that the SARI,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         , increased stage 3 sleep, while the other SARI,
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         , decreased stage 3 sleep. The SSRIs appear to increase stage 1 sleep.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – It is hypothesized that REM suppression is one mechanism for the mood elevating effects of these drugs, since REM suppression occurs with almost all antidepressants. Notable exceptions are
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         ,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         . Thus, this hypothesis is controversial. The clinical significance of stage N3 sleep enhancement is unknown.
        </p>
        <p>
        </p>
        <p>
         Tolerance to the anticholinergic/sedating effects develops relatively rapidly (usually within a week or two), while the REM-suppressing effects persist. A REM sleep rebound and sleep disturbance can be experienced with the abrupt discontinuation of REM sleep-suppressing antidepressants [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         increases total sleep time, may increase slow wave sleep, and decreases REM sleep [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Analgesics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Analgesic medications include opioids (eg,
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         ), nonsteroidal antiinflammatory drugs (NSAIDs), and antiinflammatory and antipyretic analgesics (eg,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ). Some over-the-counter (OTC) sleeping aids and cold remedies include analgesics, usually acetaminophen combined with an antihistamine. The effects of analgesic medications on sleep quality and sleep architecture have been scarcely studied.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – The effects of opioids on sleep quality differ among healthy individuals and those with opioid use disorder. In healthy individuals, opioids have no effect on wakefulness after sleep onset or total sleep time [
         <a href="#rid12">
          12,19
         </a>
         ]. By contrast, among individuals who chronically use opioids, opioids increase wakefulness after sleep onset and decrease total sleep time [
         <a href="#rid12">
          12,20
         </a>
         ]. NSAIDs may impair sleep by inhibiting prostaglandin synthesis, which is believed to promote sleep. In one study of healthy individuals, NSAIDs were associated with increased wakefulness after sleep onset, while
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         was not associated with changes in any measure of sleep quality [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – Opioids decrease stage N3 sleep and, at higher doses, also decrease REM sleep [
         <a href="#rid12">
          12
         </a>
         ]. This was demonstrated by a double-blind cross-over trial of 42 healthy volunteers [
         <a href="#rid19">
          19
         </a>
         ]. Both sustained-release
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         and
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         decreased the percentage of total sleep time spent in stage N3 sleep, compared with placebo. Neither NSAIDs nor
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         have been shown to alter sleep architecture [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Patients who receive opioids for pain may not experience sleep disturbance, as seen in patients who chronically use opioids and some healthy volunteer studies. Long-acting opiates increase daytime sleepiness.
        </p>
        <p>
        </p>
        <p>
         Tolerance to these effects develops rapidly, usually within days. Despite the adverse effects that analgesics can have on sleep in healthy individuals, analgesics may improve sleep if pain is causing a sleep disturbance [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Central nervous system stimulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications that stimulate the nervous system (eg,
         <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">
          amphetamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">
          dextroamphetamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         ,
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         ) have profound effects on both the quality and architecture of sleep [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – CNS stimulants increase the latency to sleep onset and increase wakefulness during the sleep period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – CNS stimulants increase stage N1 sleep and reduce both stage N3 and REM sleep.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Patients develop daytime sleepiness due to reduced sleep. On the other hand, stimulants are used to treat excessive daytime sleepiness in narcolepsy and others disorders of excessive sleepiness.
        </p>
        <p>
        </p>
        <p>
         Rapid tolerance develops to these effects on sleep quality and staging. Upon discontinuation of the drug, there may be increased sleepiness and a rebound in REM sleep [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Some over-the-counter medications contain
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         , which are similar in chemical structure to
         <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">
          amphetamine
         </a>
         . These agents have not been studied, but they probably also disrupt sleep.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">
          Atomoxetine
         </a>
         is a norepinephrine transporter blocker. In one study, it had no effect on nocturnal sleep latency compared with
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         but it did increase REM latency [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Caffeine disrupts sleep through its antagonistic effects on adenosine, an important regulator of the homeostatic sleep drive, and also through effects on circadian timing. In a study of healthy individuals, a dose of caffeine equivalent to that in a double espresso led to a 40-minute phase delay in the circadian melatonin rhythm [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10244238">
         <span class="h1">
          ATYPICAL ANTIPSYCHOTIC MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical antipsychotic medications are often used as hypnotics. Whereas the typical antipsychotic medications have only dopaminergic antagonism, the atypical antipsychotic medications have both serotonergic and dopaminergic antagonism.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – Studies in healthy volunteers and patients with mood disorders or schizophrenia have found that
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         reduce both sleep latency and wake time after sleep onset. Thus, the atypical antipsychotic medications increase sleep time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – Atypical antipsychotic medications generally suppress REM sleep, while increasing amounts of stage N3.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Owing to their long half-lives, daytime sedation may occur in patients receiving atypical antipsychotic medications.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CARDIAC MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac medications with an effect on sleep include the beta adrenergic blockers and centrally acting alpha adrenergic agonists.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beta blockers can be categorized as lipophilic or hydrophilic. The lipophilic agents include
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">
          pindolol
         </a>
         , while the hydrophilic agents include
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         . Hydrophilic agents do not cross the blood brain barrier readily and, thus, have no sleep effects.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – Lipophilic beta blockers are associated with an increase in both the number of awakenings and the amount of awake time following sleep onset [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture – Lipophilic and hydrophilic beta blockers both suppress REM sleep [
         <a href="#rid12">
          12,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Lipophilic beta blockers are associated with daytime sleepiness, insomnia, hallucinations, and nightmares. This effect does not appear to be secondary to their effects on nighttime sleep alone, since daytime sleepiness is observed after daytime drug administration [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Alpha adrenergic agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of the evidence regarding the impact of centrally acting alpha adrenergic receptor agonists on sleep comes from studies of one agent,
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality – The effects of alpha adrenergic receptor agonists on sleep quality are uncertain due to inconsistent data. A study of hypertensive patients found that
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         decreased total sleep time, whereas a study in healthy individuals found that clonidine increased total sleep time [
         <a href="#rid29">
          29,30
         </a>
         ]. There are limited data in children with autism spectrum disorder that clonidine may reduce sleep latency and nighttime awakenings [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture –
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         increases the number of shifts to stage N1 sleep or wakefulness, and also suppresses REM sleep [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – The alpha adrenergic receptor agonists increase daytime sleepiness. This effect is observed after daytime drug administration and does not appear to be secondary to their effects on nighttime sleep [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10620034">
         <span class="h1">
          PULMONARY MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary medications with an effect on sleep include the methylxanthines and glucocorticoids.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Theophylline
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          Theophylline
         </a>
         is a methylxanthine that is used to treat stable obstructive airways disease and, less frequently, is used as a respiratory stimulant. (See
         <a class="medical medical_review" href="/z/d/html/560.html" rel="external">
          "Theophylline use in asthma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5048.html" rel="external">
          "Management of apnea of prematurity", section on 'Caffeine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep quality –
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          Theophylline
         </a>
         delays sleep onset and increases wakefulness after sleep onset in healthy individuals. In patients with COPD and asthma, however, theophylline may have no deleterious effects on the quality of sleep. It is possible that the therapeutic effects of the drug on breathing improve sleep to such a degree that it offsets the deleterious effects of the medication on sleep [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep architecture –
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          Theophylline
         </a>
         increases stage N1 sleep, but no other effects on sleep architecture are observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient-important effects – Patients who take
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         experience improved sleep and improved daytime alertness.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoids are used to treat a variety of pulmonary diseases. They are widely believed to disrupt sleep, but this is based upon patient reports because their effects have not been well studied polysomnographically. The limited evidence that exists suggests that glucocorticoids are associated with suppression of REM sleep and increased awakening after sleep onset [
         <a href="#rid12">
          12,34
         </a>
         ]. Inhaled glucocorticoids do not appear to have the same adverse effects on sleep in most patients.
        </p>
        <p class="headingAnchor" id="H2484338211">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113803.html" rel="external">
          "Society guideline links: Insomnia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10619189">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any medication that passes through the blood-brain barrier has the potential to alter the quality and/or architecture of sleep. Sleep quality is the degree to which restful sleep is maintained during the night and the individual feels refreshed on waking and throughout the day. Sleep architecture is the structure of sleep; it is cyclical and composed of both rapid eye movement (REM) and several non-REM sleep stages. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central nervous system medications that affect sleep quality and/or sleep architecture include benzodiazepines, nonbenzodiazepine receptor agonists, antiseizure drugs, antidepressants, analgesics, and stimulants. The benzodiazepines and nonbenzodiazepine receptor agonists and orexin receptor antagonists are associated with improved ease of falling asleep, reduced awakenings, increased sleep time, less daytime sleepiness, better concentration, and better daytime performance. The other central nervous system medications have a variety of effects. (See
         <a class="local">
          'Central nervous system medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac medications that affect sleep quality and/or sleep architecture include lipophilic beta adrenergic blockers and centrally acting alpha adrenergic agonists. Both are associated with daytime sleepiness, while the lipophilic beta adrenergic blockers are also associated with insomnia, hallucinations, and nightmares. (See
         <a class="local">
          'Cardiac medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary medications known to affect sleep quality and/or sleep architecture include
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         and systemic glucocorticoids. Theophylline is associated with improved sleep and improved daytime alertness, whereas glucocorticoids are associated with increased awakening after sleep onset. (See
         <a class="local">
          'Pulmonary medications'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Kilduff TS, Mendelson WB. Mechanisms of action and pharmacologic effects. In: Principles and Practices of Sleep Medicine, 6th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St Louis, MO 2016. p.424.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2012; 26:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012; 79:2265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 2022; 21:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy P, Moline M, Mayleben D, et al. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017; 13:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark JW, Brian ML, Drummond SPA, et al. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Med Rev 2020; 53:101332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zee PC, Wang-Weigand S, Wright KP Jr, et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med 2010; 11:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emens JS, Burgess HJ. Effect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian Physiology. Sleep Med Clin 2015; 10:435.
          </a>
         </li>
         <li class="breakAll">
          Buysse DJ, Tyagi S. Clinical pharmacology of other drugs used as hypnotics. In: Principles and Practices of Sleep Medicine, 6th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St Louis, MO 2016. p.432.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005; 28:187.
          </a>
         </li>
         <li class="breakAll">
          Schweitzer PK, Randazzo A. Drugs that disturb sleep and wakefulness. In: Principles and Practices of Sleep Medicine, 6th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St Louis, MO 2016. p.480.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002; 43:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh JK, Zammit G, Schweitzer PK, et al. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006; 7:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh JK, Perlis M, Rosenthal M, et al. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006; 2:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia 2014; 55:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AH, Currie A. Physicians' knowledge of antidepressant withdrawal effects: a survey. J Clin Psychiatry 1997; 58 Suppl 7:28.
          </a>
         </li>
         <li class="breakAll">
          Peterson MJ, Benca RM. Mood disorders. In: Principles and Practice of Sleep, 4th ed, Saunders, Philadelphia 2005. p.1488.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007; 3:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin AJ, Keifer JC, Davies MF, et al. Postoperative sleep disturbance: influences of opioids and pain in humans. Sleep 2001; 24:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy PJ, Badia P, Myers BL, et al. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav 1994; 55:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glidewell RN, Moorcroft WH, Lee-Chiong T. Comorbid insomnia: Reciprocal relationships and medication management. Sleep Med Clin 2010; 5:627.
          </a>
         </li>
         <li class="breakAll">
          Nihino S, Mignot E. Wake-promoting medications: Basic mechanisms and pharmacology. In: Principles and Practices of Sleep Medicine, 6th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St Louis, MO 2016. p.446.
         </li>
         <li class="breakAll">
          O'Malley MB, Gleeson SK, Weir ID. Wake-promoting medications: Efficacy and adverse effects. In: Principles and Practices of Sleep Medicine, 5th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St. Louis, MO 2011. p.527.
         </li>
         <li class="breakAll">
          Roehrs T, Roth T. Medication and substance abuse. In: Principles and Practice of Sleep Medicine, 6th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St Louis, MO 2016. p.1380.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006; 29:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke TM, Markwald RR, McHill AW, et al. Effects of caffeine on the human circadian clock in vivo and in vitro. Sci Transl Med 2015; 7:305ra146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen RC, Kostis JB. Biobehavioral sequellae associated with adrenergic-inhibiting antihypertensive agents: a critical review. Health Psychol 1985; 4:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostis JB, Rosen RC, Holzer BC, et al. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990; 102:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanno O, Clarenbach P. Effect of clonidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors. Electroencephalogr Clin Neurophysiol 1985; 60:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008; 30:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol 1980; 10 Suppl 1:165S.
          </a>
         </li>
         <li class="breakAll">
          Schweitzer PK. Drugs that disturb sleep and wakefulness. In: Principles and Practice of Sleep Medicine, 4th ed, Saunders, 2005. p.499.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillin JC, Jacobs LS, Fram DH, Snyder F. Acute effect of a glucocorticoid on normal human sleep. Nature 1972; 237:398.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7704 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Kilduff TS, Mendelson WB. Mechanisms of action and pharmacologic effects. In: Principles and Practices of Sleep Medicine, 6th ed, Kryger MH, Roth T, Dement WC (Eds), Elsevier Saunders, St Louis, MO 2016. p.424.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22004689" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23197752" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35065036" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29065953" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32505969" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Effects of orexin receptor antagonism on human sleep architecture: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24680372" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20483660" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26568121" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian Physiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26568121" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian Physiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16171242" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16171242" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12460250" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gabapentin increases slow-wave sleep in normal adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16260179" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17557435" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24299283" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9219491" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Physicians' knowledge of antidepressant withdrawal effects: a survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9219491" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Physicians' knowledge of antidepressant withdrawal effects: a survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17557450" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The effect of opioids on sleep architecture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11204052" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Postoperative sleep disturbance: influences of opioids and pain in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8047572" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comorbid insomnia: Reciprocal relationships and medication management
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comorbid insomnia: Reciprocal relationships and medication management
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comorbid insomnia: Reciprocal relationships and medication management
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comorbid insomnia: Reciprocal relationships and medication management
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17252888" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26378246" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of caffeine on the human circadian clock in vivo and in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3913603" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Biobehavioral sequellae associated with adrenergic-inhibiting antihypertensive agents: a critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2274600" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2408846" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of clonidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280681" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Use of clonidine in children with autism spectrum disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6994771" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6994771" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4339292" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Acute effect of a glucocorticoid on normal human sleep.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
